AGA Medical to Appeal Ruling by Dutch Court in Lawsuit With Occlutech GmbH



    MINNEAPOLIS, Oct. 30 /CNW/ -- AGA Medical Holdings ("AGA Medical", "AGA")
announced today its determination to appeal a recent ruling from The Patent
Court in the Netherlands related to a proceeding brought by Occlutech GmbH,
headquartered in Jena, Germany. The lawsuit sought invalidity and/or
non-infringement declarations related to AGA Medical's claim that Occlutech
had infringed on one of its European patents for intravascular occlusion
devices and the method of forming or manufacturing these medical devices. The
company also announced its intention to file a new suit against Occlutech for
infringement of a recently issued European patent.
    The original patent was granted to AGA Medical in October 2005, and, in
August 2006, the company filed a lawsuit against Occlutech and DRABO
Medzintechnik in District Court in Dusseldorf, Germany. In July 2007, the
German court ruled that Occlutech had infringed the German patent and granted
an order prohibiting the defendants from possessing, manufacturing or selling
the infringing products. The Dutch trial court only ruled on infringement and
not on the invalidity claim and did not follow the reasoning of the German
court on infringement.
    Following the German court's decision, Occlutech appealed the ruling and
that appeal is planned to be heard in Dusseldorf in mid-November.
    With respect to the Dutch case, "AGA Medical intends to pursue an appeal
in this matter through The Hague's appellate court," said John Barr, President
and CEO of AGA Medical. "We will continue to vigorously defend our
intellectual property rights globally.  We do not believe that this ruling
will have any material impact on our business."
    
    ABOUT AGA MEDICAL
    
    AGA Medical Corporation, based in Plymouth, Minnesota (just outside
Minneapolis), is the leader in developing interventional devices to treat
structural heart defects. As a result of the many contributions and creative
genius of Dr. Kurt Amplatz, the company has developed and commercialized a
series of devices that have revolutionized the treatment of the most common
congenital "holes in the heart," such as atrial septal and patent foramen
ovale defects. The company is expanding into new areas, including the
minimally invasive repair of vascular abnormalities. Over 700 articles have
been published in peer reviewed medical publications that support the benefits
of AGA Medical devices, such as improved patient outcomes, reduced length of
stay and accelerated recovery times for the patient. AGA Medical devices have
received regulatory approval and are marketed in over 90 countries with over
250,000 devices shipped to date. For more information, visit
http://www.amplatzer.com.




For further information:

For further information: Aimee Corso of WeissComm Partners,
+1-310-780-2661, acorso@wcpglobal.com, for AGA Medical Holdings Web Site:
http://www.amplatzer.com

Organization Profile

AGA MEDICAL HOLDINGS

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890